Staff

Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis

Roflumilast cream potential “Best in Class” topical PDE4 inhibitorAtopic dermatitis affects approximately 19 million patients in the U.S.The Company anticipates...

Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Increased Funding and Support for ELX-02 Global Phase 2 Clinical Trial Program

The CF Foundation’s partial funding of the U.S. trial has been extended to partial funding of the global clinical trial...

error: Content is protected !!